Eli Lilly and (NYSE:LLY) was upgraded by equities research analysts at BMO Capital Markets from an “underperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage currently has a $79.00 target price on the stock, up from their prior target price of $74.00. BMO Capital Markets’ price target would indicate a potential downside of 0.69% from the stock’s current price. The analysts noted that the move was a valuation call.
A number of other equities research analysts have also recently issued reports on LLY. Jefferies Group set a $90.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a report on Friday. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday. Bank of America lowered their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. TheStreet cut shares of Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Finally, Credit Suisse Group reissued a “hold” rating and set a $80.00 target price on shares of Eli Lilly and in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. Eli Lilly and presently has a consensus rating of “Buy” and a consensus price target of $92.89.
LLY stock traded up $0.26 during midday trading on Friday, reaching $79.55. 1,314,146 shares of the company’s stock traded hands, compared to its average volume of 4,736,287. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. Eli Lilly and has a 52 week low of $73.69 and a 52 week high of $89.09. The stock has a market capitalization of $86,256.43, a price-to-earnings ratio of 18.53, a PEG ratio of 1.47 and a beta of 0.26.
In related news, insider Donald A. Zakrowski sold 860 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total value of $65,790.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The disclosure for this sale can be found here. Insiders sold 15,261 shares of company stock valued at $1,225,085 over the last quarter. 0.11% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in Eli Lilly and by 1.2% in the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock worth $5,393,119,000 after purchasing an additional 776,893 shares during the last quarter. Franklin Resources Inc. lifted its stake in Eli Lilly and by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock worth $2,408,787,000 after purchasing an additional 754,681 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after purchasing an additional 1,503,918 shares during the last quarter. Geode Capital Management LLC lifted its stake in Eli Lilly and by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock worth $830,522,000 after purchasing an additional 406,812 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its stake in Eli Lilly and by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock worth $560,509,000 after purchasing an additional 115,499 shares during the last quarter. Institutional investors own 77.66% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and (LLY) Raised to “Market Perform” at BMO Capital Markets” was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://dakotafinancialnews.com/2018/04/13/bmo-capital-markets-upgrades-eli-lilly-and-lly-to-market-perform.html.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.